Cullinan Therapeutics (CGEM) Short Interest Ratio & Short Volume $9.03 -0.12 (-1.31%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$9.04 +0.01 (+0.11%) As of 02/21/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Cullinan Therapeutics Short Interest DataCullinan Therapeutics (CGEM) has a short interest of 8.73 million shares, representing 23.70% of the float (the number of shares available for trading by the public). This marks a -10.74% decrease in short interest from the previous month. The short interest ratio (days to cover) is 15.7, indicating that it would take 15.7 days of the average trading volume of 466,179 shares to cover all short positions.Current Short Interest8,730,000 sharesPrevious Short Interest9,780,000 sharesChange Vs. Previous Month-10.74%Dollar Volume Sold Short$92.19 millionShort Interest Ratio15.7 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares58,228,000 sharesFloat Size36,830,000 sharesShort Percent of Float23.70%Today's Trading Volume323,682 sharesAverage Trading Volume466,179 sharesToday's Volume Vs. Average69% Short Selling Cullinan Therapeutics? Sign up to receive the latest short interest report for Cullinan Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCGEM Short Interest Over TimeCGEM Days to Cover Over TimeCGEM Percentage of Float Shorted Over Time Cullinan Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/20258,730,000 shares $92.19 million -10.7%23.7%15.7 $10.56 1/15/20259,780,000 shares $99.56 million -0.4%26.6%18.4 $10.18 12/31/20249,820,000 shares $119.61 million +1.8%26.7%19 $12.18 12/15/20249,650,000 shares $113.39 million +5.4%26.0%19.5 $11.75 11/30/20249,160,000 shares $123.20 million +5.2%24.7%16.8 $13.45 11/15/20248,710,000 shares $120.72 million -3.4%23.5%16.2 $13.86 10/31/20249,020,000 shares $140.26 million -0.4%23.0%17.1 $15.55 10/15/20249,060,000 shares $147.13 million -1.6%23.2%15.7 $16.24 9/30/20249,210,000 shares $154.18 million +9.4%23.6%14.2 $16.74 9/15/20248,420,000 shares $151.14 million +4.6%21.6%11.7 $17.95 Get the Latest News and Ratings for CGEM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20248,050,000 shares $157.78 million -1.4%20.9%10.2 $19.60 8/15/20248,160,000 shares $137.99 million -2.4%21.2%10.3 $16.91 7/31/20248,360,000 shares $161.77 million +6.0%20.6%10 $19.35 7/15/20247,890,000 shares $130.90 million +0.6%19.4%8 $16.59 6/30/20247,840,000 shares $136.73 million +73.5%19.3%8 $17.44 6/15/20244,520,000 shares $85.34 million +4.2%10.3%5.1 $18.88 5/31/20244,340,000 shares $101.99 million +16.0%11.0%5.5 $23.50 5/15/20243,740,000 shares $99.93 million +58.5%11.9%5 $26.72 4/30/20242,360,000 shares $63.74 million +40.5%10.2%3.3 $27.01 4/15/20241,680,000 shares $27.80 million +16.7%6.4%3.1 $16.55 3/31/20241,440,000 shares $24.54 million +53.9%5.5%3.4 $17.04 3/15/2024935,400 shares $14.90 million +34.8%3.6%2.3 $15.93 2/29/2024694,100 shares $12.82 million -11.5%2.6%1.8 $18.47 2/15/2024783,900 shares $14.45 million -46.7%2.9%2.3 $18.43 1/31/20241,470,000 shares $22.26 million +34.9%5.4%5.1 $15.14 1/15/20241,090,000 shares $11.54 million +3.8%4.0%5.2 $10.59 12/31/20231,050,000 shares $10.70 million -48.5%3.9%5.4 $10.19 12/15/20232,040,000 shares $16.81 million -3.3%7.5%11.1 $8.24 11/30/20232,110,000 shares $17.28 million -2.3%7.8%12.5 $8.19 11/15/20232,160,000 shares $19.16 million +0.5%8.0%13.3 $8.87 10/31/20232,150,000 shares $20.06 million -1.8%7.9%12.9 $9.33 10/15/20232,190,000 shares $19.27 million -0.5%8.1%12.9 $8.80 9/30/20232,200,000 shares $19.91 million +0.9%8.1%12.1 $9.05 9/15/20232,180,000 shares $21.71 million -17.7%8.0%11.5 $9.96 8/31/20232,650,000 shares $27.43 million +33.2%9.8%10.2 $10.35 8/15/20231,990,000 shares $20.32 million +2.6%7.4%6.4 $10.21 7/31/20231,940,000 shares $20.54 million -18.5%8.2%6.1 $10.59 7/15/20232,380,000 shares $27.89 million +15.5%10.1%7.6 $11.72 6/30/20232,060,000 shares $22.17 million -11.6%8.7%6.8 $10.76 6/15/20232,330,000 shares $29.59 million +2.6%9.9%7.6 $12.70Here’s how you could profit from Elon’s NVIDIA partnership (Ad)"Elon's #1 AI Stock" SET TO SOAR Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world. Get all the details here >>> 5/31/20232,270,000 shares $23.34 million +0.9%9.6%8.6 $10.28 5/15/20232,250,000 shares $22.37 million +0.5%9.5%10.7 $9.94 4/30/20232,240,000 shares $21.80 million +0.5%9.5%10.7 $9.73 4/15/20232,230,000 shares $22.34 million +0.5%9.5%9.9 $10.02 3/31/20232,220,000 shares $22.71 million +1.8%9.4%10.2 $10.23 3/15/20232,180,000 shares $24.44 million +3.8%7.7%10.5 $11.21 2/28/20232,100,000 shares $23.71 million +1.5%7.0%13.3 $11.29 2/15/20232,070,000 shares $23.91 million +6.7%6.9%13.7 $11.55 1/31/20231,940,000 shares $22.58 million -9.4%6.6%13.7 $11.64 1/15/20232,140,000 shares $23.50 million -1.8%7.2%16.4 $10.98 12/30/20222,180,000 shares $23.00 million No Change7.4%17 $10.55 12/15/20222,180,000 shares $24.96 million No Change7.4%15.9 $11.45 11/30/20222,180,000 shares $27.10 million -5.6%7.4%14.8 $12.43 11/15/20222,310,000 shares $29.48 million -4.9%8.0%14.2 $12.76 10/31/20222,430,000 shares $31.93 million -0.4%8.5%15.4 $13.14 10/15/20222,440,000 shares $30.79 million -1.2%8.5%15.7 $12.62 9/30/20222,470,000 shares $31.67 million +14.4%8.6%14.2 $12.82 9/15/20222,160,000 shares $28.21 million -13.6%7.5%10.9 $13.06 8/31/20222,500,000 shares $33.70 million No Change8.8%10.5 $13.48 8/15/20222,500,000 shares $35.40 million +2.9%8.8%8.5 $14.16 7/31/20222,430,000 shares $32.83 million -17.9%9.9%4.1 $13.51 7/15/20222,960,000 shares $43.57 million -1.7%12.1%4.9 $14.72 6/30/20223,010,000 shares $38.59 million -0.7%12.3%5.2 $12.82 6/15/20223,030,000 shares $36.09 million +6.3%12.4%5.2 $11.91 5/31/20222,850,000 shares $30.47 million +4.0%11.7%5.3 $10.69 5/15/20222,740,000 shares $29.10 million +3.8%11.2%5.7 $10.62 4/30/20222,640,000 shares $25.90 million +7.8%11.2%14.4 $9.81 4/15/20222,450,000 shares $27.44 million -3.5%10.4%13.2 $11.20 3/31/20222,540,000 shares $26.59 million -7.3%11.0%13.3 $10.47 3/15/20222,740,000 shares $34.91 million +1.5%12.1%13.2 $12.74 2/28/20222,700,000 shares $38.72 million +5.9%12.0%10.3 $14.34 2/15/20222,550,000 shares $37.69 million -3.4%11.3%9.6 $14.78 1/31/20222,640,000 shares $35.59 million -13.7%12.1%9.9 $13.48 1/15/20223,060,000 shares $41.89 million -1.0%13.4%11.4 $13.69 12/31/20213,090,000 shares $47.68 million +27.2%14.3%10.7 $15.43 12/15/20212,430,000 shares $38.71 million +3.4%11.2%9.4 $15.93 11/30/20212,350,000 shares $42.30 million -0.8%10.9%9.9 $18.00 11/15/20212,370,000 shares $49.68 million -7.8%8.1%9.3 $20.96 10/29/20212,570,000 shares $57.11 million +0.8%8.9%10.3 $22.22 10/15/20212,550,000 shares $63.75 million -1.9%8.8%10.6 $25.00 9/30/20212,600,000 shares $58.68 million +42.9%9.0%11.7 $22.57 9/15/20211,820,000 shares $52.78 million -24.5%6.3%7.6 $29.00 8/31/20212,410,000 shares $68.01 million -11.1%8.4%11.7 $28.22 8/13/20212,710,000 shares $75.09 million No Change9.5%12.4 $27.71 CGEM Short Interest - Frequently Asked Questions What is Cullinan Therapeutics' current short interest? Short interest is the volume of Cullinan Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, investors have sold 8,730,000 shares of CGEM short. 23.70% of Cullinan Therapeutics' shares are currently sold short. Learn More on Cullinan Therapeutics' current short interest. What is a good short interest ratio for Cullinan Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CGEM shares currently have a short interest ratio of 16.0. Learn More on Cullinan Therapeutics's short interest ratio. Which institutional investors are shorting Cullinan Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cullinan Therapeutics: Group One Trading LLC, Citadel Advisors LLC, Jane Street Group LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cullinan Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.70% of Cullinan Therapeutics' floating shares are currently sold short. Is Cullinan Therapeutics' short interest increasing or decreasing? Cullinan Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 8,730,000 shares, a drop of 10.7% from the previous total of 9,780,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cullinan Therapeutics' float size? Cullinan Therapeutics currently has issued a total of 58,228,000 shares. Some of Cullinan Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cullinan Therapeutics currently has a public float of 36,830,000 shares. How does Cullinan Therapeutics' short interest compare to its competitors? 23.70% of Cullinan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cullinan Therapeutics: Centessa Pharmaceuticals plc (3.38%), HUTCHMED (China) Limited (0.24%), Kymera Therapeutics, Inc. (11.87%), Bausch Health Companies Inc. (2.37%), Vera Therapeutics, Inc. (16.56%), Protagonist Therapeutics, Inc. (6.36%), Beam Therapeutics Inc. (12.10%), Harmony Biosciences Holdings, Inc. (9.32%), CG Oncology, Inc. (15.21%), Janux Therapeutics, Inc. (17.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Cullinan Therapeutics stock? Short selling CGEM is an investing strategy that aims to generate trading profit from Cullinan Therapeutics as its price is falling. CGEM shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cullinan Therapeutics? A short squeeze for Cullinan Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CGEM, which in turn drives the price of the stock up even further. How often is Cullinan Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CGEM, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies CNTA Short Interest Data HCM Short Interest Data KYMR Short Interest Data BHC Short Interest Data VERA Short Interest Data PTGX Short Interest Data BEAM Short Interest Data HRMY Short Interest Data CGON Short Interest Data JANX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CGEM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
